Characterization of CD13 and CD33 Surface Antigen–Negative Acute Myeloid Leukemia

Abstract

Prostatic adenocarcinoma rarely may involve the urinary bladder. Prostatic adenocarcinoma and high-grade transitional cell carcinoma (TCC) may coexist and account for the malignant cells seen in urinary cytology. Differentiating prostatic adenocarcinoma cells from those of TCC is important for therapy but remains difficult. A 10-year retrospective search identified 250 patients with high-grade carcinoma in urinary cytology. Among them, 6 cases of tissue-documented prostate adenocarcinoma were identified. The cytologic features of these cases were compared with those of 15 similarly documented cases of high-grade TCC. By using these criteria, 2 additional cases of prostatic adenocarcinoma were diagnosed prospectively. An oval nucleus with smooth borders; fine, powdery, evenly distributed nuclear chromatin and a large prominent nucleolus when present; and lack of significant pleomorphism are most helpful to differentiate prostatic adenocarcinoma from high-grade TCC. Recognizing these cells may be the first clue for the diagnosis of prostate adenocarcinoma.

Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters

“…It is abnormally expressed and regulated in leukaemic B cells and recent studies have been invaluable in improving leukaemia and lymphoma classification systems [4,6,8,15,[25][26][27]. For instance, CD23 has been found to be expressed by cells in B small lymphocyte lymphoma (SLL)/chronic lymphocytic leukaemia (CLL) and absent in a majority of cases of mantle cell lymphoma (MCL) while all three disorders coexpress CD5 [28,29]; CD23 has also been found on monocytes, minor subsets of T cells, eosinophils and dendritic cells [17,27].…”

“…After two washes in 2% FCS/PBS pH 7.2, MNCs were counted and underwent immediate immunophenotype analysis. PBL \ 100 9 10 9 /l greater than 1 year 78 (%) PBL [ 100 9 10 9 /l less than 1 year 43 (%) Francisco, CA) using a standard assay [25]. The following monoclonal antibodies were used in the study: CD2, CD5, CD7, CD11b, CD25, CD38, HLA-DR, kappa and lambda obtained from Ortho Pharma, USA; CD10, CD20 and CD23 obtained from Coulter, USA; CD3, CD4, CD8, CD19, CD22 and CD45 obtained from Behring, Germany.…”

Novel surface tagging technology for selection of complex proliferation‐controlled mammalian cell phenotypes

“…In principle, SEAP could be exchanged by any product gene (for proliferation-controlled production processes) or disease-correcting gene (for gene therapy concepts) and Hook could be replaced by other endogenous or heterologous surface markers. FACS-mediated cell sorting based on expression of endogenous surface antigens is a standard technology for enrichment of cell populations (de Wynter et al, 1995;de Wynter et al, 1999;Kraguljac et al, 2000;Lai et al, 2000;Porwitt-MacDonald et al, 2000). For example, CD34 hematopoietic progenitor cells of Gaucher patients were enriched by FACS and transduced using a dicistronic retroviral vector encoding the wild-type glucocerebrosidase gene for correction of Gaucher disease and a CD24 or HSA (heat-stable antigen) surface marker.…”

“…Although antibiotic-based selection is routinely used for biotechnological applications, it is not compatible with in vivo selection of desired cell phenotypes in humans. The increasing knowledge of surface antigens expressed during dierent developmental stages or on diseased cells enables new opportunities for cell surface-based selection technologies (de Wynter et al, 1995, de Winter et al, 1999Kraguljac et al, 2000;Lai et al, 2000;Porwitt-MacDonald et al, 2000).…”

Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy

“…CD13 is expressed in approximately 75% of cases of AML but not by acute lymphoblastic or CLL cells (247). Anti-CD13 MoAbs are extensively used in the phenotyping of neoplasms of myeloid origin (248)(249)(250).…”